Genzyme pursues innovation in discovery and development and the strategic acquisition of new resources. Our ability to execute creates the opportunities to support long-term growth.

We are strengthening our orthopaedics franchise by assuming full control, including sales and marketing, of Synvisc, a product used to treat pain of osteoarthritis of the knee. We continue to invest in the development of next-generation products and in expanding indications. Thymoglobulin, our antibody immunosuppressant, is already a leader in several major world markets. We are expanding it into new geographies and into new uses, such as transplant of other organs or as induction treatment prior to transplant. In the United States and Europe, we are pursuing the expansion of Thyrogen, our thyroid cancer diagnostic, into remnant ablation.